[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Choi J, Lim H, Nam DK, Kim HS, Cho DY, Yi JW, Kim HC, Cho YK, Kim MW, Joo HJ, Lee KB, Kim KB: Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer; 2001 Jan;84(2):186-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
  • We evaluated the expression of thymidylate synthase (TS) in locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection and investigated the association between TS expression and clinicopathologic characteristics including prognosis of the patients.
  • TS expression was evaluated by immunohistochemical staining using TS106 monoclonal antibody in 103 locally advanced gastric cancer patients (stage IB-IV) who underwent 5-fluorouracil (5-FU) and doxorubicin-based adjuvant chemotherapy after curative resection.
  • High TS expression was associated with male gender (P = 0.002), poorly differentiated histology (P = 0.015), and mixed type in Lauren's classification (P = 0.027).
  • In conclusion, although high TS expression was associated with poorly differentiated histology and mixed type in Lauren's classification, it did not predict poor disease-free and overall survival in gastric cancer patients treated with 5-FU and doxorubicin-based adjuvant chemotherapy after curative resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Thymidylate Synthase / drug effects
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Stomach / drug effects. Stomach / enzymology. Stomach / pathology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):379-89 [8658222.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):397-406 [8658224.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):766-72 [8795580.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1923-31 [9164203.001]
  • [Cites] Gen Diagn Pathol. 1997 Jul;143(1):39-48 [9269907.001]
  • [Cites] Cancer. 1998 May 1;82(9):1626-31 [9576280.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1469-74 [9626464.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1300-6 [9762929.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2054-9 [9827708.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):805-10 [10216496.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • [Cites] Mol Pharmacol. 1984 Jan;25(1):171-7 [6708932.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] Hepatogastroenterology. 1989 Feb;36(1):7-12 [2744714.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] Yonsei Med J. 1989 Sep;30(3):256-68 [2588662.001]
  • [Cites] Cancer. 1991 May 15;67(10):2454-8 [2015545.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4306-12 [1643628.001]
  • [Cites] Ann Surg. 1992 Sep;216(3):269-78; discussion 278-9 [1417176.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Lancet. 1994 May 7;343(8906):1122-6 [7910230.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1106-10 [7734309.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2757-63 [7595735.001]
  • (PMID = 11161374.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 80168379AG / Doxorubicin; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2363711
  •  go-up   go-down


2. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB: Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer; 2002 May 20;86(10):1578-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
  • Both 5-fluorouracil and doxorubicin are commonly used agents in chemotherapy of gastric cancer in adjuvant setting as well as metastatic disease.
  • We evaluated the expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase using immunohistochemistry in 103 locally advanced gastric cancer patients (stage IB-IV) who underwent 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection and investigated the association between their expression and clinicopathologic characteristics including prognosis of the patients.
  • High multidrug resistance-associated protein1 and P-glycoprotein expressions were associated with well and moderately differentiated histology (P<0.0001 and P=0.03, respectively) and intestinal type (P<0.0001 and P=0.009, respectively).
  • High multidrug resistance-associated protein1 expression correlated with lymph node metastasis (P=0.037), advanced stage (P=0.015), and older age (P=0.021).
  • In conclusion, high expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase did not predict poor prognosis of gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Gastrectomy. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Thymidylate Synthase / analysis
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunotherapy. Lentinan / administration & dosage. Life Tables. Male. Middle Aged. Mitomycin / administration & dosage. Picibanil / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] comCopyright 2002 Cancer Research UK
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):1903-6 [9677442.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1461(2):359-76 [10581367.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):171-7 [10638986.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6C):4809-14 [11205224.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):186-92 [11161374.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):116-24 [2562856.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 7;82(21):1679-83 [1977924.001]
  • [Cites] Cancer. 1991 May 15;67(10):2454-8 [2015545.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4306-12 [1643628.001]
  • [Cites] Science. 1992 Dec 4;258(5088):1650-4 [1360704.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] J Surg Oncol. 1995 Jan;58(1):63-9 [7823576.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2757-63 [7595735.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):231-8 [8532000.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1681-7 [8608562.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):379-89 [8658222.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):372-7 [8903480.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1923-31 [9164203.001]
  • [Cites] Oncology. 1997 Sep-Oct;54(5):391-9 [9260601.001]
  • [Cites] Br J Cancer. 1997;76(4):486-93 [9275026.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1300-6 [9762929.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1231-7 [9816292.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2054-9 [9827708.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):673-80 [10100721.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):805-10 [10216496.001]
  • [Cites] Surg Today. 1999;29(5):401-6 [10333409.001]
  • [Cites] Br J Cancer. 1998;77(1):87-91 [9459150.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):661-6 [9477097.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1533-42 [9626474.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • (PMID = 12085207.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 37339-90-5 / Lentinan; 39325-01-4 / Picibanil; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2746581
  •  go-up   go-down


3. Zhao AG, Cao W, Xu Y, Zhao G, Liu BY, Cai Y, Yang JZ, Gu Y, Yuan W, Zhu YJ, Han YY, Yang JY: [Survival benefit of an herbal formula for invigorating spleen for elderly patients with gastric cancer]. Zhong Xi Yi Jie He Xue Bao; 2010 Mar;8(3):224-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival benefit of an herbal formula for invigorating spleen for elderly patients with gastric cancer].
  • BACKGROUND: Gastric cancer is one of the most common malignant tumors.
  • Traditional Chinese medicine (TCM) has been widely used in treatment of gastric cancer, but still lacking large sample controlled trial to evaluate its efficacy.
  • OBJECTIVE: To analyze the prognostic factors of 220 elderly patients with gastric cancer, and to further study the efficacy of an herbal formula for invigorating spleen and it modifications based on syndrome differentiation of TCM in treatment of gastric cancer in elderly patients and the influence on prognosis.
  • DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A total of 220 elderly patients aged 65 years or over with gastric cancer from Longhua Hospital of Shanghai University of Traditional Chinese Medicine, and Renji Hospital and Ruijin Hospital of Shanghai Jiao Tong University Medical College were prospectively enrolled.
  • Patients in the TCHM group were treated with an herbal formula for invigorating spleen plus chemotherapy, while patients in the non-TCHM group were only treated with chemotherapy.
  • Kaplan-Meier curves were used to assess the differences in survival time between TCHM group and non-TCHM group after stratification for TNM stage, surgery or chemotherapy.
  • RESULTS: The 220 eligible patients were histologically confirmed adenocarcinoma of the stomach from 2001 to 2007.
  • Eighty-nine cases in the TCHM group received three or more months of TCHM treatment, and 131 cases in the non-TCHM group did not receive TCHM treatment.
  • Cox regression analysis suggested that the TNM stage, radical resection, three or more treatment cycles of chemotherapy, and TCHM treatment were independent prognostic factors (P<0.01).
  • The patients receiving TCHM treatment demonstrated better prognosis than the other prognostic factors in multivariate analysis; the odds ratio [Exp(beta)] of overall group was 0.322, and 95% confidence interval (CI) was from 0.212 to 0.489.
  • In stratification analysis of stage for 96 patients who did not accepted radical resection or suffered from recurrence and metastasis (36 cases in the TCHM group, and 60 cases in the non-TCHM group), Cox regression analysis suggested that three or more treatment cycles of chemotherapy and TCHM treatment were independent prognostic factors for improving survival respectively (P<0.01).
  • The hazard ratio [Exp(beta)] of TCHM in stratification for late stage was 0.421, and 95% confidence interval was from 0.255 to 0.693.
  • In stratification analysis of surgery and chemotherapy for 102 patients with Ib-IV (M0) who accepted radical resection (R0 resection) and three or more treatment cycles of chemotherapy (33 cases in the TCHM group, and 69 cases in the non-TCHM group), the disease-free survival and overall survival did not reach the median at the time of analysis.
  • CONCLUSION: The herbal formula for invigorating spleen has an important value for improving the prognosis of elderly patients with gastric cancer.
  • This herbal formula show survival benefit for advanced gastric cancer in elderly patients.
  • The influence of TCHM on disease-free survival and overall survival of postoperative gastric cancer in elderly patients need to be further evaluated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Drugs, Chinese Herbal / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Drug Combinations. Female. Humans. Male. Medicine, Chinese Traditional. Prognosis. Prospective Studies. Spleen. Survival

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20226143.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


Advertisement
4. Rino Y, Sekino Y, Yamada T, Nakayama T, Arai H, Kanari M, Saeki H, Yukawa N, Wada N, Masuda M, Higashida T, Imada T: [Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1095-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports].
  • We treated two patients in whom irinotecan (CPT-11)+cisplatin (CDDP) and irradiation showed efficacy against brain metastases of gastric cancer.
  • In March 2003, he was diagnosed as having Stage IV gastric cancer with peritoneal dissemination (T3, Nx, P1) and underwent total gastrectomy with D1 dissection.
  • Chemotherapy with S-1 was continued after surgery.
  • The weekly paclitaxel (PTX) therapy was tried instead.
  • Seven months later, he developed headache and weakness, and multiple brain metastases were diagnosed by CT scanning.
  • We performed total brain irradiation (30 Gy) and started CPT-11+CDDP therapy, which was continued on a fortnightly basis at 60 mg/m(2) and 30 mg/m(2), respectively.
  • The brain metastases regressed (PR), and this therapy led to a marked improvement in his quality of life.
  • In November 2003, he was diagnosed as having stage IB gastric cancer (T2 (ss), N0, P0), and underwent total gastrectomy and splenectomy with D2 dissection.
  • S-1, S-1+CDDP, and weekly PTX therapy were all tried.
  • We then performed Cyber Knife treatment and administered CPT-11+CDDP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Radiosurgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Gastrectomy. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Quality of Life. Radiotherapy Dosage. Remission Induction. Splenectomy

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637547.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Higuchi K, Phan A, Ajani JA: Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol; 2003 Oct;4(5):413-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer: advances in adjuvant and adjunct therapy.
  • Patients with gastric carcinoma remain at high risk for local and systemic relapses, even after a successful surgery (R0 resection).
  • The trials with positive results from chemotherapy or chemoimmunotherapy have not gained global acceptance.
  • In North America, where gastric surgery is often less than optimal, the Intergroup 0116 trial has provided evidence of benefit in overall survival time and time-to-cancer progression for patients treated with postoperative chemoradiotherapy.
  • This trial recruited 556 patients with resected gastric cancer from stage IB through IV and an R0 resection was mandatory for registration.
  • In our opinion, all of the patients in the West who have had a curatively resected node-positive gastric carcinoma (R0 resection) should be offered an option of receiving postoperative chemoradiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1657-68 [10547537.001]
  • [Cites] Ann Surg. 1968 Mar;167(3):293-312 [4966925.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1036-9 [9508188.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2757-63 [7595735.001]
  • [Cites] Cancer. 1991 May 15;67(10):2454-8 [2015545.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Cancer. 1985 May 1;55(9):1868-73 [3884131.001]
  • [Cites] World J Surg. 1988 Jun;12(3):374-81 [3400248.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Dec;29(13):2499-507 [12506472.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1249-54 [6491703.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):1105-12 [6349780.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):549-52 [8595173.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:211-3 [9101834.001]
  • [Cites] Cancer. 1965 Mar;18:291-7 [14264030.001]
  • [Cites] Cancer. 1979 Aug;44(2):385-91 [113074.001]
  • [Cites] Acta Med Austriaca. 1989;16(3-4):68-9 [2692375.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):970-4 [8164049.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1357-62 [2262358.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1362-9 [2199622.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer. 1978 Mar;41(3):941-7 [638980.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1116-22 [7037156.001]
  • [Cites] Br J Surg. 1989 Jun;76(6):535-40 [2758258.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2733-8 [9704725.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):431-44, xii-xiii [12424861.001]
  • [Cites] Gastric Cancer. 1999 Nov;2(3):151-157 [11957089.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1309-12 [7910321.001]
  • [Cites] Lancet. 1989 Mar 18;1(8638):571-4 [2564109.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):347-54 [9742917.001]
  • (PMID = 12941201.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic
  • [Number-of-references] 43
  •  go-up   go-down


6. Kunisaki C, Makino H, Kimura J, Takagawa R, Kosaka T, Ono HA, Akiyama H, Fukushima T, Nagahori Y, Takahashi M: Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery; 2010 Feb;147(2):204-11
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymphovascular invasion in patients with stage I gastric cancer.
  • BACKGROUND: Patients with stage I gastric cancer often suffer from tumor recurrence despite a generally favorable operative outcome.
  • METHODS: Between April 1985 and March 2000, a total of 1,880 patients with histologically proven stage I gastric cancer were included in this study.
  • Operative outcomes (survival time, prognostic factors, pattern of recurrence) were evaluated in these patients.
  • RESULTS: Multivariate analysis in patients with all stage I gastric cancer revealed that depth of invasion, lymph node metastasis, and lymphovascular invasion independently influenced prognosis.
  • Moreover, advanced age was selected as an independent prognostic factor in patients with stage IA, and lymphovascular invasion in patients with stage IB gastric cancer by multivariate analyses.
  • The 5-year survival rates in stage T1N1 patients with moderate to severe lymphovascular invasion, T2N0 with moderate to severe lymphovascular invasion, and II were 95.1%, 83.5%, and 76.9%, respectively.
  • There was a significant difference in survival time between stage T1N1 and II (P = .0189) but not between stage T1N1 and T2N0 or stage T2N0 and II.
  • CONCLUSION: T2N0 gastric cancer patients with moderate to severe lymphovascular invasion may be suitable candidates for adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 19878963.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Park JM, Kim YH: Current approaches to gastric cancer in Korea. Gastrointest Cancer Res; 2008 May;2(3):137-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current approaches to gastric cancer in Korea.
  • Gastric cancer remains a significant global health problem and is the most common cancer in Korea.
  • Surgery is the only curative treatment for localized gastric cancer, but most cases present at an advanced stage.
  • The proportion of early gastric cancer and the incidence of gastric cancer located in the upper third of the stomach have increased in Korea.
  • The majority of patients in Korea receive surgery alone or surgery plus chemotherapy.
  • The 5-year survival rate with curative resection is 55.6%-66.0%, with rates of 92.9%-98.0%, 84.2%-92.0%, 69.3%-72.0%, 45.8%-54.0%, 29.6%-36.5%, and 9.2%-23.9% according to TNM stages of Ia, Ib, II, IIIa, IIIb, and IV, respectively.
  • Recently, Korean investigators have played pivotal roles in studies initiated by global pharmaceutical companies, and the Korean Cancer Study Group has initiated 14 multicenter trials, including phase III trials in gastric cancer and international cooperative trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 May 21;96(10):1514-9 [17473829.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):631-7 [17520252.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Am J Clin Oncol. 1996 Apr;19(2):212-6 [8610653.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Oncologist. 2007 May;12(5):543-54 [17522242.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):623-9 [17522863.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(5):837-45 [17579864.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jul;37(7):501-8 [17673470.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):295-301 [10023695.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17(2):132-8 [10449685.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1109-15 [10506693.001]
  • [Cites] J Clin Gastroenterol. 2001 Jan;32(1):37-40 [11154167.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2288-93 [11413517.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Gastroenterol. 2001 Dec;36(12):816-22 [11777209.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):531-5 [11802218.001]
  • [Cites] Am J Gastroenterol. 2002 May;97(5):1106-12 [12014714.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jul;32(7):248-54 [12324575.001]
  • [Cites] Gastric Cancer. 2002;5(3):177-82 [12378346.001]
  • [Cites] Jpn J Clin Oncol. 2002 Aug;32(8):275-6 [12411563.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1779-85 [12419751.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1893-8 [12453857.001]
  • [Cites] J Korean Med Sci. 2003 Feb;18(1):53-7 [12589087.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):383-7 [12598342.001]
  • [Cites] Int J Cancer. 2003 Oct 10;106(6):953-60 [12918076.001]
  • [Cites] Ann Surg. 1992 Sep;216(3):269-78; discussion 278-9 [1417176.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1329-33 [15054450.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):18-22 [15188010.001]
  • [Cites] J Korean Med Sci. 2004 Jun;19(3):369-73 [15201502.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1344-7 [15319239.001]
  • [Cites] J Surg Oncol. 2004 Oct 1;88(1):9-13 [15384089.001]
  • [Cites] Am J Clin Oncol. 2004 Oct;27(5):477-80 [15596914.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):246-51 [15655540.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):827-31 [15726097.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):188-94 [15803015.001]
  • [Cites] Jpn J Clin Oncol. 2005 May;35(5):251-5 [15886269.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):188-93; discussion 193-4 [15895442.001]
  • [Cites] Jpn J Clin Oncol. 2005 Jul;35(7):380-5 [15976069.001]
  • [Cites] Oncology. 2005;68(2-3):190-5 [16006756.001]
  • [Cites] Oncology. 2005;68(4-6):333-40 [16020960.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85 [16099596.001]
  • [Cites] Korean J Intern Med. 2005 Jun;20(2):135-40 [16134768.001]
  • [Cites] Am J Clin Oncol. 2005 Oct;28(5):433-8 [16199979.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):720-6 [16332718.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):727-32 [16332720.001]
  • [Cites] Anticancer Drugs. 2006 Feb;17(2):225-9 [16428942.001]
  • [Cites] Oncology. 2006;70(1):63-70 [16446551.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):621-7 [16465422.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):959-63 [16552439.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1402-6 [16641896.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1407-11 [16641916.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jan;59(1):17-21 [16721549.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jan;37(1):30-7 [17272321.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Nov;60(6):863-9 [17333192.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):157-65 [17426971.001]
  • [Cites] Eur J Surg Oncol. 2008 Jan;34(1):36-41 [17442532.001]
  • [Cites] Acta Oncol. 2007;46(3):336-41 [17450469.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):263-70 [17960386.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Feb;61(2):315-21 [18026677.001]
  • [Cites] Cancer Res Treat. 2006 Feb;38(1):13-8 [19771253.001]
  • [Cites] Cancer Res Treat. 2005 Dec;37(6):325-31 [19956367.001]
  • [Cites] Int J Epidemiol. 1995 Feb;24(1):33-41 [7797354.001]
  • [Cites] World J Surg. 1994 Nov-Dec;18(6):872-7; discussion 877-8 [7846911.001]
  • [Cites] J Korean Med Sci. 1998 Dec;13(6):612-6 [9886169.001]
  • (PMID = 19259291.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2633072
  •  go-up   go-down


8. Strauss J, Hershman DL, Buono D, McBride R, Clark-Garvey S, Woodhouse SA, Abrams JA, Neugut AI: Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. Int J Radiat Oncol Biol Phys; 2010 Apr;76(5):1404-12
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival.
  • PURPOSE: In randomized trials patients with resected nonmetastatic gastric cancer who received adjuvant chemotherapy and radiotherapy (chemoRT) had better survival than those who did not.
  • We investigated the effectiveness of adjuvant chemoRT after gastric cancer resection in an elderly general population and its effects by stage.
  • METHODS AND MATERIALS: We identified individuals in the Surveillance, Epidemiology, and End Results-Medicare database aged 65 years or older with Stage IB through Stage IV (M0) gastric cancer, from 1991 to 2002, who underwent gastric resection, using multivariate modeling to analyze predictors of chemoRT use and survival.
  • RESULTS: Among 1,993 patients who received combined chemoRT or no adjuvant therapy after resection, having a later year of diagnosis, having a more advanced stage, being younger, being white, being married, and having fewer comorbidities were associated with combined treatment.
  • Among 1,476 patients aged less than 85 years who survived more than 4 months, the 313 who received combined treatment had a lower mortality rate (hazard ratio, 0.83; 95% confidence interval, 0.71-0.98) than the 1,163 who received surgery alone.
  • Adjuvant therapy significantly reduced the mortality rate for Stages III and IV (M0), trended toward improved survival for Stage II, and showed no benefit for Stage IB.
  • CONCLUSIONS: The association of combined adjuvant chemoRT with improved survival in an overall analysis of Stage IB through Stage IV (M0) resected gastric cancer is consistent with clinical trial results and suggests that, in an elderly population, adjuvant chemoradiotherapy is effective.
  • However, our observational data suggest that adjuvant treatment may not be effective for Stage IB cancer, is possibly appropriate for Stage II, and shows significant survival benefits for Stages III and IV (M0) for those aged less than 80 years.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3408-15 [9363873.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):314-9 [9010104.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):428-34 [10468896.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1198-205 [10519898.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(1):41-7 [16184457.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):660-9 [17582625.001]
  • [Cites] Ann Epidemiol. 2007 Aug;17(8):584-90 [17531502.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):500-7 [18026800.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1073-80 [17905529.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Ann Epidemiol. 2000 May;10(4):224-38 [10854957.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Soc Sci Med. 2001 Dec;53(11):1513-24 [11710426.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2643-50 [12039925.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-43-8 [12187167.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-49-54 [12187168.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] Med Care. 2003 Mar;41(3):442-6 [12618647.001]
  • [Cites] J Am Geriatr Soc. 1985 Sep;33(9):585-9 [4031335.001]
  • [Cites] JAMA. 1986 Jun 27;255(24):3385-90 [3712698.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] JAMA. 1987 May 22-29;257(20):2766-70 [3573271.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):377-83 [8293403.001]
  • [Cites] Med Care. 1998 Sep;36(9):1337-48 [9749657.001]
  • (PMID = 19540074.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024156; United States / NCRR NIH HHS / RR / ULI RR024156; United States / NCI NIH HHS / CA / R25 CA094061; United States / NCI NIH HHS / CA / K07 CA132892-04; United States / NCI NIH HHS / CA / CA132892-04; United States / NCI NIH HHS / CA / CA094061; United States / NCI NIH HHS / CA / K07 CA132892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS455659; NLM/ PMC3617616
  •  go-up   go-down


9. Căinap C, Părău A, Muntean A, Hodorog A, Vlad L: [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy]. Chirurgia (Bucur); 2010 Jan-Feb;105(1):31-6
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy].
  • [Transliterated title] Chimioterapia de generaţie nouă in cancerul gastric operat--o alternativă la chimioterapia clasică.
  • Gastric cancer remains one of the most difficult tumour type despite his relative reduction of his global incidence, it remains on of the most deadly cancer.
  • The latest advances in therapy of the gastric cancer ameliorate the results in terms of survival.
  • In our prospective, non-randomized study, we enrolled 40 patients with gastric adenocarcinoma stage IB to IV (M0) who were surgically treated, treated with chemoradioterapy, but with chemotherapy modified by ECX (epirubicine, cisplatine, xeloda) which is now considered standard in metastatic setting.
  • The ECX regimen seems to be a reliable alternative to the traditional regimen with convenient toxicity and therapeutic index.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Capecitabine. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405677.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Tsang WK, Leung SF, Chiu SK, Yeung WW, Ng EK, Yeo W, Lam KC, Chiu PW, Ma BB, Kwan WH, Chan AT: Adjuvant chemoradiation for gastric cancer: experience in the Chinese population. Clin Oncol (R Coll Radiol); 2007 Jun;19(5):333-40
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation for gastric cancer: experience in the Chinese population.
  • AIMS: The role of adjuvant chemoradiation for gastric cancer after curative R0 gastrectomy was first established by the US Intergroup 0116 study.
  • We describe our radiotherapy technique and report the treatment results in Hong Kong.
  • MATERIALS AND METHODS: This was a single centre retrospective study on 63 Chinese patients who underwent adjuvant chemoradiation for gastric adenocarcinoma between June 2000 and December 2004.
  • The treatment protocol was based on that of the Intergroup study.
  • Computed tomography planned anteroposterior opposing field arrangement and treatment under breath hold at deep inspiration position were adopted.
  • RESULTS: In total, 63 patients, mean age 50 years, with gastric cancer stage IB to limited metastatic IV disease were analysed.
  • The median follow-up time was 27.2 months.
  • The recurrence pattern was dominated by distant failure and only one patient developed isolated locoregional recurrence.
  • CONCLUSIONS: The outcome after adjuvant chemoradiation for gastric cancer seemed to be favourable, with manageable toxicities, in the Chinese population.
  • [MeSH-major] Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Hong Kong / ethnology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434719.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Kawaoka T, Matsukuma S, Nagashima A, Hiraki S, Fukuda S: [A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2415-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy].
  • He had a history of laparoscopic-assisted distal gastrectomy for gastric cancer about 11 months ago.
  • The stage was IB and pathological examination was poorly differentiated adenocarcinoma.
  • The pathological diagnosis was recurrent of gastric cancer.
  • After percutaneous transhepatic cholangio drainage (PTCD) and jejunotomy, the chemotherapy with low-dose CDDP and 5-FU followed by weekly paclitaxel was performed.
  • The patient lived for 8 months after chemotherapy.
  • It is important to understand that gastric cancer diagnosed poorly differentiated adenocarcinoma pathologically sometimes occurs duodenal invasion and obstructive jaundice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Duodenum / pathology. Jaundice, Obstructive / etiology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Duodenal Neoplasms / pathology. Duodenal Obstruction / etiology. Fluorouracil / administration & dosage. Gastrectomy. Humans. Laparoscopy. Male. Middle Aged. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224591.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; Familial duodenal atresia
  •  go-up   go-down


12. Bruno L, Nesi G, Nobili S, Veltri M, Girardi LR, Boni D, Santomaggio C, Neri B, Boddi V, Bechi P, Mini E, Cortesini C: Postoperative chemotherapy in resected gastric cancer: results of a single center experience. J Chemother; 2008 Aug;20(4):497-502
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative chemotherapy in resected gastric cancer: results of a single center experience.
  • Gastric cancer remains a major health problem despite its decline in incidence in Western countries.
  • Although radical surgery represents the primary curative option for gastric cancer patients, most of them relapse and die due to their disease despite an R0 resection.
  • At present the routine use of postoperative adjuvant therapy to reduce disease recurrence is still considered an investigational approach.
  • Out of a total of 275 patients (stage IB through IV M0 AJCC/UICC) who underwent surgery for gastric cancer at our Surgery Unit between 1993 and 2001, 156 were eligible for adjuvant chemotherapy, of whom only 52 accepted to undergo this treatment.
  • Five-year survival was 40% in the chemotherapy group and 37.8% in the group which underwent surgery alone.
  • Indeed, chemotherapy did not reduce the risk of death (HR 0.87, 95% CI = 0.57-1.34, p=0.54).
  • The current study did not show a clear advantage of chemotherapy over surgery alone.
  • However, our results can help to define strategies for future clinical trials with the use of new regimens based on more effective and less toxic drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676232.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Cartenì G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G, Gruppo Oncologico Italia Meridionale: Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol; 2007 Aug;18(8):1354-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
  • BACKGROUND: This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients.
  • PATIENTS AND METHODS: From June 1996 to June 2001, 228 stage IB-IIIB gastric cancer patients were enrolled.
  • All patients received a total or subtotal gastrectomy with at least a D1 lymphoadenectomy and were randomly assigned to receive surgery alone or surgery followed by chemotherapy.
  • With a median follow-up of 60 months, the 5-year overall survival (OS) was 48% in the treatment arm and 43.5% in the control arm [hazard ratio (HR) 0.91; 95% confidence interval (CI) 0.69-1.21; P = 0.610); the 5-year disease-free survival (DFS) was 44% in the treatment arm and 39% in the control arm (HR 0.88; 95% CI 0.78-0.91; P = 0.305).
  • In node-positive patients, the 5-year OS was 41% in the treatment arm and 34% in the control arm (HR 0.84; 95% CI 0.69-1.01; P = 0.068), while the 5-year DFS was 39% in the treatment arm and 31% in the control arm (HR 0.88; 95% CI 0.78-0.91; P = 0.051).
  • CONCLUSIONS: In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525087.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Mares JE, Yao J, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani JA, Xie K: Sp1 expression is associated with increased VEGF, advanced stage, and poor survival in patients with resected gastric cancer (GC). J Clin Oncol; 2004 Jul 15;22(14_suppl):4039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sp1 expression is associated with increased VEGF, advanced stage, and poor survival in patients with resected gastric cancer (GC).
  • METHODS: GC tissue from 86 patients who had gastrectomy at the University of Texas M.D.
  • Anderson Cancer Center was evaluated for expression of Sp1 and VEGF by Western blot and immunohistochemistry.
  • None had pre-operative chemotherapy and/or radiation.
  • Early (stage IA) GC was associated with negative and weak Sp1 expression while more advanced GC (IB-IV) was associated with strong expression (P=.035).
  • Sp1 and VEGF expression, stage, completeness of resection, age, and histology were entered in a multivariate Cox proportional hazards model.
  • Strong Sp1 expression (P=.021) and advanced stage (P<.001) were the only independent predictors of poor survival.
  • Sp1 may be a useful molecular marker for selecting patients with a poor prognosis to receive more aggressive preoperative or adjuvant therapy in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014374.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lee J, Kang W, Lim D, Park J, Park Y, Lim H, Sohn T, Noh J, Bae J, Kim S: Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis.
  • : 4537 Background: Although the adjuvant chemoradiation therapy has gained popularity and has become the standard of care in patients with resected gastric cancer in U.S., the role of chemoradiation therapy after extended D2 dissection has been questioned.
  • We conducted a phase III trial to compare capecitabine/cisplatin (XP) vs XP + radiotherapy (RT) in curatively D2 resected gastric cancer patients in terms of disease free survival and overall survival.
  • METHODS: Eligibility criteria were as follows: stage Ib (T1N1, T2bN0) - IV (M1 excluded), curatively ≥ D2 resected gastric adenocarcinoma.
  • XP only: X 2,000 mg/m<sup>2</sup>/d D1∼14, CDDP 60 mg/m<sup>2</sup> D1 repeated every 3 weeks, 6 cycles; XP + RT: X 2,000 mg/m<sup>2</sup>/d D1∼14, CDDP 60 mg/m<sup>2</sup> D1 x 2 cycles ⋄ RT 45 Gy (25 fractions) + X 1,650 mg/m<sup>2</sup>/d during RT ⋄ X 2,000 mg/m<sup>2</sup>/d D1∼14, CDDP 60 mg/m<sup>2</sup> D1 x 2 cycles.
  • In XP arm, 172 (75%) of 228 enrolled patients completed 6 cycles of chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962988.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol; 2009 May 20;27(15_suppl):4515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008).
  • : 4515 Background: INT0116 (SWOG 9008) was a prospectively randomized phase III trial of postoperative adjuvant therapy utilizing 5-FU/leucovorin plus external beam radiation in 582 eligible cases of resected stage IB-IV(M0) stomach and gastroesophageal junction cancers.
  • Subset analyses were performed for sex, race, T and N stage, D-level of surgical resection, tumor location (proximal or other), histology (intestinal or diffuse) and Maruyama index.
  • In women the HR for therapy was 1.0(0.68-1.45).
  • The HR for therapy in diffuse histology cases was 0.97(0.62-1.40).
  • Second tumors represented a spectrum of types of neoplasms commonly occurring in this age group (median age 60 years).
  • Excessive numbers of tumors known to be caused by radiation and/or chemotherapy were not noted.
  • CONCLUSIONS: With >10 years median follow-up, survival remains improved in stage IB-IV (M0) gastric cancer cases treated with post-operative chemoradiaiton.
  • All subsets benefit from this treatment with the exception of cases with diffuse histology.
  • Women may be more likely to have diffuse histology gastric cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962700.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kang S, Hwang Y, Lee H, Jeong S, Choi J, Jo Y, Han S, Kim J, Han J: Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection. J Clin Oncol; 2009 May 20;27(15_suppl):4562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection.
  • : 4562 Background: A few studies reported the association between helicobacter pylori (HP) infection and better overall survival (OS) in resected gastric cancer patients (pts).
  • METHODS: We investigated the HP infection status and its association with clinicopathologic characteristics in 210 locally advanced gastric cancer patients (stage IB: 18, II: 61, IIIA: 62, IIIB: 31, IV: 38) who underwent adjuvant chemotherapy (CTX) after curative resection (≥D2 dissection).
  • HP infection status in hematoxlin and eosin stained peritumoral tissue was graded according to the updated Sydney System and categorized as HP(-) (normal or mild infection) and HP(+) (moderate or marked infection) (Am J Surg Pathol 20:1161, 1996).
  • Twenty-two pts received 5-FU, doxorubicin (DOX) CTX (5- FU 500 mg/m2 weekly for 36 wks, DOX 40 mg/m2 q 3 weeks x 12) with or without OK432, while 188 pts underwent 5-FU, mitomycin-C (MMC), and polysaccharide-K (PSK) CTX (5-FU 500 mg/m2 weekly for 24 wks, MMC 8 mg/m2 q 6 wks x 4, PSK 3 g/day for 16 wks) (Br J Cancer 84:186, 2001, Hepatogastroenterol 54:290, 2007).
  • HP (-) was significantly correlated with Bormann type IV, larger tumor size (>5.5cm),and stage IIIB.
  • HP(-) was associated with poor outcome in all stages except stage IB (p=0.075).
  • In multivariate analysis, HP(-) was the most significant independent prognostic factor of poor OS (hazard ratio 9.646, 95% CI 5.407-17.206, p<0.0001) followed by advanced stage (p=0.032), Bormann type IV (p=0.037) and old age (p=0.015).
  • CONCLUSIONS: HP infection status seems to have strong prognostic significance in locally advanced gastric cancer.
  • HP (-) pts may need intensified adjuvant treatment and careful follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Altinbas M, Kaplan B, Ucar K, Ozkan M, Karahacioglu E, Er O, Kucuk C, Soyuer I: 5-FU plus leucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4196

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-FU plus leucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study.
  • : 4196 Background: Patients with locoregionally advanced carcinoma of the stomach have a grim outcome due to frequent local and systemic recurrences after surgery.
  • To potentially increase the local control or survival rate and decrease relapses, we investigated a strategy of concurrent chemoradiotherapy and followed by consolidation chemotherapy after surgery.
  • METHODS: Operable 71 patients (Stage IB-IV, M0) underwent total or subtotal gastrectomy.
  • Adjuvant chemotherapy (250 mg/m2 5-FU) was administered concurrently on the first day of every radiotherapy weeks [which was totally standart field radiotherapy (RT), or total abdominal field RT up to 20 Gy first, then returned to standart field RT], .
  • After chemoradiotherapy regimen, consolidation chemotherapy consisted of 450 mg/mg 5-FU plus 20 mg/m2 Leucovorin was applied up to four cycles, q28 d.
  • Six patients in both arms did not get consolidation chemotherapy.
  • There were no deaths related to chemotherapy, chemoradiotherapy, or surgery.
  • CONCLUSIONS: Preliminary results suggest the feasibility of postoperative adjuvant chemoradiotherapy with 5-FU followed by consolidation chomotherapy with MAYO regimen in gastric cancer with acceptable toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ebisui C, Souma I, Hayashi N, Fukuchi N, Izawa H, Yoshida T, Sakita I, Hasuike Y, Fujimoto T: [A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1861-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
  • Her final findings were of pT2, pN0, sP0, sH0, sM0 and Stage IB.
  • She underwent a weekly administration of paclitaxel (90 mg/body) as a second-line chemotherapy.
  • Although the prognosis of recurrent gastric cancer with peritoneal dissemination was extremely poor, this case might suggest a possibility that intensive therapies are useful in maintaining the quality of life and improving survival.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antimetabolites, Antineoplastic / therapeutic use. Hydronephrosis / drug therapy. Oxonic Acid / therapeutic use. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. Pyridines / therapeutic use. Stents. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Combined Modality Therapy. Drug Combinations. Female. Gastrectomy. Humans. Lymph Node Excision. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Peritonitis / drug therapy. Peritonitis / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553740.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


20. Tamura S, Miki H, Okada K, Yoshimura M, Uji K, Yoshida A, Suzuki R, Nakahira S, Egawa C, Nakata K, Okamura S, Sugimoto K, Takatsuka Y: [Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2024-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer].
  • The prognosis of patients with T3 gastric cancer is poor, even if a curative resection is performed.
  • Novel combination neo-adjuvant chemotherapy has been introduced for T3 gastric cancer patients.
  • They were diagnosed with gastric cancer with serosal invasion (T3) without P1 and CY1 by staging laparoscopy.
  • We selected a combined chemotherapy with both paclitaxel and S-1.
  • After one course of this therapy, surgery was performed.
  • After one course, four patients underwent a total gastrectomy and one distal gastrectomy.
  • The final histological stagings were included one stage IB, one stage II, one stage IIIA, one stage IIIB, and one stage IV.
  • Three patients died at 10, 11, and 16 months after the initial treatment, and two have survived for 64 and 62 months.
  • As the intraperitoneal administration of paclitaxel and oral S-1 was well-tolerated, further studies should be conducted involving T3 gastric cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / administration & dosage. Oxonic Acid / therapeutic use. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / administration & dosage. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Combinations. Humans. Injections, Intraperitoneal. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106511.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Yao JC, Ajani JA: Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep; 2002 May;4(3):222-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant and preoperative chemotherapy for gastric cancer.
  • Gastric cancer is the second most frequently diagnosed malignancy worldwide, and the risk of relapse remains high in the majority of patients undergoing resection.
  • Attempts to reduce this risk and prolong survival have led to numerous adjuvant chemotherapy trials that either had no benefit for patients or occasionally had controversial results.
  • In this Intergroup trial, which involves over 600 patients, a regimen of postoperative chemotherapy plus chemoradiotherapy was shown to prolong overall and disease-free survival in gastric cancer patients with stage IB through IV disease following a curative (R0) resection.
  • This approach should be considered the standard of care in patients with gastric cancer who have undergone curative resection.
  • Preoperative chemotherapy shows promise in downstaging tumors and increasing the rate of curative resection, but randomized trials are needed to assess survival benefits.
  • Efforts to combine existing treatment modalities and new agents with novel mechanisms of action hold promise for the future.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1993 Mar-Apr;17(2):256-61; discussion 261-2 [8511923.001]
  • [Cites] Eur J Cancer. 1993;29A(3):340-2 [8398330.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1501-6 [1893349.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1657-68 [10547537.001]
  • [Cites] Ann Surg. 1968 Mar;167(3):293-312 [4966925.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1036-9 [9508188.001]
  • [Cites] Gastric Cancer. 1998 Mar;1(2):125-133 [11957056.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2757-63 [7595735.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Cancer. 1991 May 15;67(10):2454-8 [2015545.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):1-8 [6360325.001]
  • [Cites] Cancer. 1985 May 1;55(9):1868-73 [3884131.001]
  • [Cites] Recent Results Cancer Res. 1988;110:44-51 [3043596.001]
  • [Cites] Cancer. 1990 Dec 1;66(11):2324-30 [1700927.001]
  • [Cites] Ann Surg. 1983 Jul;198(1):13-7 [6407408.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1249-54 [6491703.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):549-52 [8595173.001]
  • [Cites] J Clin Oncol. 1996 Jun;14 (6):1818-28 [8656250.001]
  • [Cites] World J Surg. 1977 Mar;2(1):213-21 [868069.001]
  • [Cites] Cancer. 1965 Mar;18:291-7 [14264030.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44 [8230264.001]
  • [Cites] Cancer. 1979 Aug;44(2):385-91 [113074.001]
  • [Cites] Acta Med Austriaca. 1989;16(3-4):68-9 [2692375.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):970-4 [8164049.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):629-31 [1347336.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1362-9 [2199622.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1248-52 [7552009.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1116-22 [7037156.001]
  • [Cites] Br J Surg. 1988 Nov;75(11):1100-4 [2905188.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2733-8 [9704725.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1269-75 [7999411.001]
  • [Cites] Ann Surg. 1992 Sep;216(3):269-78; discussion 278-9 [1417176.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] Cancer. 1997 May 1;79(9):1767-75 [9128994.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1309-12 [7910321.001]
  • [Cites] Lancet. 1989 Mar 18;1(8638):571-4 [2564109.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):347-54 [9742917.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 11937012.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


22. Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC: Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol; 2007 Oct;14(10):2730-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
  • BACKGROUND: We evaluated the long-term natural history of gastric cancer after radical gastrectomy and adjuvant chemotherapy through a 15-year follow-up study at a single institute.
  • METHODS: Five hundred patients with advanced gastric adenocarcinoma who received radical gastrectomy and adjuvant chemotherapy were included in this long-term follow-up study.
  • Tumor stage was a clear-cut prognosticator within 5 years post gastrectomy, but was no longer informative in 5-10 years.
  • At this period, only stage IV (IB-IIIB vs IVM0) was a significantly poor prognosticator.
  • After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases).
  • CONCLUSIONS: In patients with gastric carcinoma treated with radical gastrectomy and adjuvant chemotherapy, late recurrence after 5 years post gastrectomy was not rare.
  • Prognosticators were varied depending on the length of time after surgery.
  • Tumor factors including stage were prognosticators within 5 years post gastrectomy, but tumor factors except stage IV had no prognostic value after 5 years.
  • In the 5-10 years post gastrectomy, only stage IV (IB-IIIB vs IVM0) was a poor prognosticator.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Prognosis. Survival Rate. Survivors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632757.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg; 2000 Jan;135(1):81-7; discussion 88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
  • HYPOTHESIS: Neoadjuvant therapy has the potential to induce regression of high-risk, locally advanced cancers and render them resectable.
  • Preoperative chemoradiotherapy is proposed as a testable treatment concept for locally advanced pancreatic cancer.
  • DESIGN: Fourteen patients (8 men, 6 women) with locally advanced pancreatic cancer were surgically explored to exclude distant spread of disease, to perform bypass of biliary and/or gastric obstruction, and to provide a jejunostomy feeding tube for long-term nutritional support.
  • A course of chemotherapy with fluorouracil and cisplatin plus radiotherapy was then initiated.
  • Reexploration and resection were planned subsequent to neoadjuvant therapy.
  • INTERVENTIONS: Surgically staged patients with locally advanced pancreatic cancer were treated by preoperative chemotherapy with bolus fluorouracil, 400 mg/m2, on days 1 through 3 and 28 through 30 accompanied by a 3-day infusion of cisplatin, 25 mg m2, on days 1 through 3 and 28 through 30 and concurrent radiotherapy, 45 Gy.
  • RESULTS: Of 14 patients who enrolled in the protocol and were initially surgically explored, 3 refused the second operation and 11 were reexplored; 2 showed progressive disease and were unresectable and 9 (81%) had definitive resection.
  • Surgical pathologic stages of the resected patients were: Ib (2 patients), II (2 patients), and III (5 patients).
  • Pathologic response: 2 patients had apparent complete pathologic response; 1 patient had no residual cancer in the pancreatectomy specimen, the other patient who had an iridium 192 interstitial implant had normal core biopsies of the pancreatic head.
  • Five patients had minimal residual cancer in the resected pancreas or microscopic foci only with extensive fibrosis, and 2 patients had fully viable residual cancer.
  • In the definitive surgery group the median survival was 19 months after beginning chemoradiotherapy and 16 months after definitive surgery.
  • The absolute 5-year survival was 11% of 9 patients, 1 is surviving 96 months (with no evidence of disease) after chemoradiotherapy and extended pancreatic resection including resection of the superior mesenteric artery and the portal vein for stage III cancer.
  • CONCLUSION: A pilot study of preoperative chemoradiotherapy with infusional cisplatin and radiation induced a high rate of clinical pathologic response in patients with locally advanced pancreatic cancer and merits further study in these high-risk patients.
  • [MeSH-major] Neoadjuvant Therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Radiotherapy Dosage. Reoperation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10636353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


24. Morimoto J, Oohira M, Kubo N, Tanaka H, Dan N, Muguruma K, Yashiro M, Sawada T, Yamashita Y, Nishiguchi Y, Hirakawa K: [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2436-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy].
  • Various examinations revealed an esophageal cancer with direct invasion to the left main bronchus (cT4, N2 (104R, 106recR), M0, Stage IVa) and gastric cancer (cT2, N0, M0, Stage IB).
  • The patient was given preoperative chemoradiotherapy (40 Gy/20 fr with CDGP 10 mg/body day 1-5, 8- 12, 15-19 and 5-FU 250 mg/body day 1-5, 8-12, 15-19).
  • After the chemoradiotherapy, we estimated that the esophageal cancer was down stage (cT4-->T3), and that a curative operation was possible.
  • Pathological therapeutic evaluation of the esophageal cancer was complete response (CR) and the gastric cancer was T2, N0.
  • Adjuvant chemotherapy was undergone with S-1.
  • However, two years after the first operation, we found a recurrence of gastric duct.
  • Therefore a surgical resection for recurrence of gastric duct was performed.
  • The patient is still alive without recurrence 5 years and 2 months after the first treatment.
  • Radiation therapy combined with nedaplatin and 5-FU is a safe and effective method for treating cT4 advanced esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Esophagectomy. Fluorouracil / administration & dosage. Gastrectomy. Humans. Male. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy. Organoplatinum Compounds / administration & dosage. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037448.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Yao JC, Ajani JA: Gastric cancer. Curr Opin Gastroenterol; 2000 Nov;16(6):516-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer.
  • Gastric adenocarcinoma is the most common malignancy of the upper gastrointestinal tract.
  • Recent research suggests that a number of biologic and molecular differences exist in patients with gastric cancer.
  • Further investigation in these areas may help in predicting outcome and directing therapy.
  • Gastric cancer is not a curable condition when metastases are present.
  • However, postoperative chemotherapy plus chemoradiotherapy, in the Intergroup trial 0116, prolonged the overall and disease-free survival rates of patients after a curative (R0) resection.
  • It should be considered the new standard of care in patients with gastric cancer who have undergone curative resection with stage Ib-IV disease.
  • Preoperative therapy strategies may increase the likelihood of R0 resection and remain an area of active investigation.
  • Finally, development of more active agents is needed for the treatment of metastatic tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031130.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ringash J, Khaksart SJ, Oza A, Couture J, Japp B, Moore M, Siu LL, Hedley D, Swallow C, Wong S, Cummings B, Kim J, Wong R, Brierley J: Post-operative radiochemotherapy for gastric cancer: adoption and adaptation. Clin Oncol (R Coll Radiol); 2005 Apr;17(2):91-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-operative radiochemotherapy for gastric cancer: adoption and adaptation.
  • AIMS: Intergroup study 0116 (INT-0116) showed an 11% absolute improvement in 3-year survival with post-operative radiochemotherapy for gastric cancer, but reported 33% severe acute GI toxicity using conventional simulation with large fields.
  • We adapted the treatment using conformal radiotherapy techniques and assessed toxicity and outcome in 20 consecutive patients.
  • METHODS: A conformal radiotherapy technique previously developed for gastric lymphoma was adapted to treat the target volume defined in INT-0116.
  • Consecutive patients with ECOG PS 0-2 and stage IB-IV non-metastatic gastric cancer were treated with 5-FU (425 mg/m2 daily x 5 days) and leucovorin (20 mg/m2 daily x 5 days) for one cycle prior to and two cycles following concurrent radiation (45 Gy/25 fractions) with identical drug dosages on the first 4 and last 3 days of radiation.
  • RESULTS: Nineteen of 20 patients completed radiotherapy and 14 completed all chemotherapy cycles.
  • Survival is comparable to that achieved in the INT-0116 treatment arm (approximately 60% at 2 years).
  • INT-0116 results can be achieved outside a study setting; however, further efforts to improve treatment efficacy and minimize toxicity are warranted.
  • [MeSH-major] Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Outcome Assessment (Health Care). Radiotherapy, Conformal. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830570.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK: A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol; 2002 Nov;13(11):1779-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
  • BACKGROUND: A phase III single-center randomized trial was performed in order to determine whether the addition of mitomycin C (MMC) and/or doxorubicin to 5-fluorouracil (5-FU) as adjuvant chemotherapy could influence survival in patients with curatively resected gastric cancer.
  • PATIENTS AND METHODS: A total of 416 patients who had undergone curative resection for stage IB-IIIB gastric adenocarcinoma were stratified according to the stage and type of surgery, and then randomized to receive one of the three chemotherapy regimens, 5-FU alone (F) or 5-FU and MMC (FM) or 5-FU, doxorubicin and MMC (FAM) within 5 weeks after surgery.
  • CONCLUSIONS: Compared with adjuvant 5-FU alone, the addition of MMC and/or doxorubicin to 5-FU did not influence survival in patients with resected gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Treat Rev. 2003 Apr;29(2):131-3 [12670457.001]
  • (PMID = 12419751.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Mlkvý P: Multimodal therapy of gastric cancer. Dig Dis; 2010;28(4-5):615-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of gastric cancer.
  • Adenocarcinoma of the stomach is the 2nd most common cancer worldwide.
  • The 5-year survival rates after curative surgical resection decline from 60-90% in stage I, to 30-50% in stage II and finally drop to only to 10-25% for patients in stage III of this disease.
  • Surgical treatment is the only therapeutic modality that has a potentially curative effect.
  • According to certain criteria, early gastric cancer limited to the mucosa or submucosa is indicated for endoscopic mucosal resection.
  • In advanced gastric cancer with surgical approach, the questions of type of resection, extent of lymph node dissection and indication for splenectomy do arise.
  • Chemotherapy is the treatment of choice in stage IV for unresectable disease.
  • According to numerous randomized controlled trials, adjuvant chemotherapy versus chemoradiotherapy have been accepted for stages Ib-IIIb of this disease.
  • Combination chemotherapy seems to be more effective than monotherapy.
  • Neoadjuvant chemotherapy is administered with the aim to downstage a locally advanced tumor prior to attempting curative resection.
  • New therapeutic possibilities include agents like angiogenesis inhibitors, human epidermal growth factor receptor family inhibitors and inhibitors of small molecules (tyrosine kinase inhibitors).
  • Survival rates in resectable gastric cancer are influenced mainly by the depth of invasion through the gastric wall and by the presence or absence of regional lymph node involvement.
  • [MeSH-major] Stomach Neoplasms / therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088412.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


29. Choi JH, Kim YB, Lim HY, Park JS, Kim HC, Cho YK, Han SW, Kim MW, Joo HJ: 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion. Hepatogastroenterology; 2007 Jan-Feb;54(73):290-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
  • BACKGROUND/AIMS: Although adjuvant chemotherapy has demonstrated small but significant survival benefit in locally advanced gastric cancer in several meta-analyses, optimal chemotherapy regimen remains to be determined.
  • METHODOLOGY: We retrospectively analyzed the survival of 207 gastric cancer patients (stage IB: 19, II: 65, IIIA: 58, IIIB: 28, IV: 37) who underwent 5-fluorouracil (5-FU), mitomycin-C (MMC), and polysaccharide-K (PSK) chemoimmunotherapy (CITX) after curative resection (FM group).
  • The survival of FM group was compared with that of historical control cohort of 103 patients with almost identical stage distribution who received 5-FU and doxorubicin-based chemotherapy (FA group).
  • FM group showed superior 5-year OS (84.4% vs. 67.6%, p = 0.019) compared with FA group in stage IB or II patients without significant difference (p = 0.222) in stage IIIA to IV.
  • CONCLUSIONS: 5-FU, MMC, and PSK CITX is as effective as 5-FU and doxorubicin-based chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Mitomycin / administration & dosage. Peripheral Nerves / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Immunotherapy. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419278.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Kadokawa Y, Sonoda K, Nakajima S, Kawabe A, Egawa H: [Advanced gastric cancer in an elderly woman showing histopathologic CR after a course of S-1 and CDDP combination therapy]. Gan To Kagaku Ryoho; 2010 Apr;37(4):711-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced gastric cancer in an elderly woman showing histopathologic CR after a course of S-1 and CDDP combination therapy].
  • An 80-year-old woman was diagnosed with advanced gastric cancer of T2N0H0P0M0, Stage IB.
  • Because the performance status (PS)was 1, combination chemotherapy with S1 100 mg/day (day 1-21) and CDDP 50 mg/m2 (day 8) was initiated.
  • After one course of treatment was completed, she changed her mind and expressed the wish to undergo an operation for her disease, which led to proximal gastrectomy (double tract reconstruction) being performed.
  • A histopathological examination revealed CR of the disease with no cancer cells.
  • As the population grows older, the number of elderly patients with advanced gastric cancer will increase in the future.
  • Therefore, S-1 and CDDP combination therapy may be a treatment of choice for gastric cancer with dose reduction according to patient status, if the elderly patient refuses a curative operation.
  • It may well prove to be an effective treatment in the elderly provided the dosage and administration are appropriate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Combined Modality Therapy. Drug Combinations. Female. Humans. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414032.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Kim JP, Yu HJ, Lee JH: Results of immunochemo-surgery for gastric carcinoma. Hepatogastroenterology; 2001 Sep-Oct;48(41):1227-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of immunochemo-surgery for gastric carcinoma.
  • BACKGROUND/AIMS: Although the therapeutic results of gastric cancer have markedly improved, it still remains the most common cancer death in Korea.
  • METHODOLOGY: The clinicopathologic characteristics were analyzed for 11,491 consecutive patients who underwent operation for gastric cancer at the Department of Surgery, Seoul National University Hospital from 1971 to 1997.
  • The prognostic significance of treatment modality [surgery alone, surgery + chemotherapy, surgery + immunotherapy + chemotherapy (immunochemo-surgery)] were evaluated in stage III gastric cancer.
  • The 5-year survival rates according to TNM stage were 92.9% for Ia, 84.2% for Ib, 69.3% for II, 45.8% for IIIa, 29.6% for IIIb and 9.2% for IV.
  • Regarding adjuvant treatment modality, significant survival difference was observed in stage III patients.
  • The 5-year survival rates were 44.8% for the immunochemo-surgery group, 36.8% for the surgery + chemotherapy group and 27.2% for the surgery alone group.
  • CONCLUSIONS: Curative resection, depth of invasion and lymph node metastasis were the most significant prognostic factors in gastric cancer.
  • Consequently, early detection and curative resection with radical lymph node dissection, followed by immunochemotherapy especially in patients with stage III gastric cancer should be recommended as a standard treatment principle for patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Picibanil / therapeutic use. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11677936.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 39325-01-4 / Picibanil
  •  go-up   go-down


32. Oblak I, Velenik V, Anderluh F, Strojan P: Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia. Eur J Surg Oncol; 2007 Oct;33(8):982-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia.
  • AIMS: To analyze the results of postoperative concomitant radiochemotherapy with 5-florouracil (5-FU) and leucovorin (LV) in patients with gastric carcinoma treated in a single institution.
  • METHODS: During 2001-2004, 123 patients with the mean age of 60 years, were treated for adenocarcinoma of the stomach, stage Ib-IV, with postoperative concomitant radiochemotherapy.
  • Adjuvant treatment consisted of five cycles of five-day chemotherapy with 5-FU (425 mg/m(2)) and LV (20 mg/m(2)) and concomitant radiotherapy with the total dose of 45 Gy.
  • RESULTS: The treatment was completed according to the protocol in 101 patients.
  • The median follow-up time of 87 survivors was 30.4 months (range 17.4-58.3 months).
  • In the multivariate analysis, the initial Hb level was identified as independent prognostic factor for all survival four endpoints, the involvement of whole stomach with cancer for LRC, the total dose of 5-FU per five-day cycle for DFS, and pT stage for DSS.
  • CONCLUSIONS: In operable gastric carcinoma, postoperative concomitant radiochemotherapy with 5-FU and LV is feasible and its toxicity acceptable.
  • Its potential to improve the treatment outcome compared to the surgery alone is yet to be tested in well designed prospective randomized studies.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiation Dosage. Radiotherapy, Adjuvant. Risk Factors. Slovenia / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258881.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Lu Y, Liu C, Zhang R, Li H, Lu P, Jin F, Xu H, Wang S, Chen J: Prognostic significance of subclassification of pT2 gastric cancer: a retrospective study of 847 patients. Surg Oncol; 2008 Dec;17(4):317-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of subclassification of pT2 gastric cancer: a retrospective study of 847 patients.
  • PURPOSE: To investigate the prognostic significance of subclassification of pT2 gastric cancers according to the nodal status.
  • METHODS: Clinicopathological characteristics and prognostic outcomes of 847 gastric cancer patients who received a gastrectomy between 1985 and 2003 were retrospectively evaluated based on the subclassification of pT2 stage (i.e. pT2a and pT2b).
  • RESULTS: Of the patients, 244 and 603 had pT2a and pT2b stage cancers, respectively.
  • Multivariate analysis identified age, tumor location, pT stages, pN stages, and adjuvant chemotherapy as independent prognostic factors for pT2 gastric cancers.
  • The survival rates were similar between pT2aN1 (stage II) and pT2bN0 (stage IB) cancers (P=0.604), and between pT2aN2 (stage IIIA) and pT2bN1 (stage II) cancers (P=0.936).
  • CONCLUSIONS: Subclassification of pT2 gastric cancers into pT2a or pT2b is of prominent prognostic significance, and thus it is recommended that the current stage grouping conventions include subclassification of pT2, in order to more accurately predict the prognosis of patients.
  • [MeSH-major] Neoplasm Staging / methods. Stomach Neoplasms / classification. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586486.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Kassam Z, Lockwood G, O'brien C, Brierley J, Swallow C, Oza A, Siu L, Knox JJ, Wong R, Cummings B, Kim J, Moore M, Ringash J: Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):713-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
  • BACKGROUND: The Intergroup 0116 study showed a survival benefit with adjuvant chemoradiotherapy (CRT) for resected gastric cancer.
  • METHODS AND MATERIALS: Eighty-two patients with resected gastric or gastroesophageal junction (GEJ) adenocarcinoma, Stage IB to IV (M0), were treated with 45 Gy in 25 fractions using a 5-field conformal technique.
  • Chemotherapy was in accordance with the Intergroup 0116 study, or infusional 5-fluorouracil and cisplatin in a phase I/II trial.
  • Grade 3 or greater acute toxicity (National Cancer Institute Common Terminology Criteria of Adverse Events, version 3.0) was noted in 57% of patients (upper gastrointestinal tract 34%, hematologic 33%).
  • Radiation Therapy Oncology Group Grade 3 late toxicity included esophageal strictures (3 patients) and small bowel obstruction (1 patient).
  • CONCLUSION: Adjuvant CRT for gastric cancer, even with conformal RT, is associated with significant toxicity.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Radiotherapy, Conformal. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Esophagogastric Junction. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626887.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Espín F, Bianchi A, Llorca S, Pulido L, Felíu J, de-la-Cruz J, Palomera E, García O, Remon J, Suñol X: Large lymph node size harvested as prognostic factor in gastric cancer? Rev Esp Enferm Dig; 2010 Mar;102(3):169-75
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large lymph node size harvested as prognostic factor in gastric cancer?
  • OBJECTIVE: Knowledge regarding prognostic factors in gastric cancer is essential to decide on single patient management.
  • MATERIAL AND METHODS: Charts of one hundred and twenty-eight consecutive patients undergoing gastrectomy for resectable gastric cancer were reviewed between January 1996 and December 2005.
  • Overall five-year survival related to cancer were analyzed as a main endpoint.
  • Nevertheless, a significant difference has been found according to T1-T2 of TNM stage (78.1 vs. 39.1% p = < 0.001), for N grade staging, has statistical signification for grade N0 (62.7 vs. 30.5%; p < 0.001), and for Ia and Ib stages (57.6 vs. 17.4%).
  • CONCLUSIONS: Our data indicates that large lymph node size could be a powerful predictor for overall survival in gastric cancer, when it could be evaluated in preoperative period.
  • In our opinion lymph node size should be considered for perioperative chemotherapy schemas.
  • Detection and staging techniques for lymph node affection acquire much more importance.
  • [MeSH-major] Lymph Nodes / pathology. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20373831.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


36. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol; 2006 Aug 20;24(24):3953-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
  • PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal.
  • Combined-modality therapy quality, survival, and safety were secondary end points.
  • PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible.
  • Patients received two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiation and chemotherapy (infusional fluorouracil and weekly paclitaxel).
  • Quality of therapy was assessed with other end points.
  • Forty-nine patients were entered and 43 were assessable (12% stage IB; 37% stage II; and 52% stage III).
  • Chemotherapy, radiotherapy, and surgery per protocol (including acceptable variations) occurred in 98%, 44%, and 63% of patients, respectively.
  • CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting.
  • With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921048.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


37. Cheng JC, Liu MC, Tsai SY, Fang WT, Jer-Min Jian J, Sung JL: Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer; 2004 Nov 1;101(9):2126-33
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-two patients with Stage IB-IV gastric/gastroesophageal adenocarcinoma without metastases underwent radical total/subtotal gastrectomy; regional lymph node dissection; and postoperative, adjuvant, concomitant chemoradiotherapy (CCRT).
  • Among these, 8 patients developed CRILD (defined as Grade 3-4 liver toxicity), and 11 patients were chronic hepatitis B virus (HBV) carriers (HBV+).
  • Chemotherapy consisted of 1 cycle of etoposide, leucovorin, and 5-fluorouracil (ELF); followed by 5 weekly high doses of 5-fluorouracil (2000-2600 mg/m2) and leucovorin concurrent with radiotherapy (median dose, 45 grays [Gy] to the tumor bed/regional lymphatics); followed by 3 cycles of ELF separated by a 21-day interval.
  • HBV-negative patients with CRILD were recipients of a higher mean liver dose (MLD) (23.8 Gy vs. 15.2 Gy; P = 0.009) and a higher volume fraction of liver that received > 30 Gy (36.5% vs. 19.7%; P = 0.009) compared with noncarriers without CRILD, but no MLD difference was found between HBV+ patients with or without CRILD.
  • [MeSH-major] Gastrectomy / adverse effects. Hepatitis B virus / physiology. Liver Diseases / etiology. Stomach Neoplasms / therapy. Virus Activation
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389480.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Kiyama T, Tajiri T, Yoshiyuki T, Mitsuhashi K, Ise Y, Mizutani T, Okuda T, Fujita I, Masuda G, Kato S, Matsukura N, Tokunaga A, Hasegawa S: [Clinical significance of a standardized clinical pathway in gastrectomy patients]. J Nippon Med Sch; 2003 Jun;70(3):263-9
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In traditional practice patterns, physicians take care of all clinical decisions, such as diagnosis, treatment, and recovery.
  • In the Nippon Medical School Hospital a clinical pathway for distal gastrectomy patients, recorded as a post-operative care map, was introduced in August 2000.
  • In January 2001 the post-operative management was analyzed and standardization of practice was carried out with printed order sets, such as drugs and infusion solutions.
  • PATIENTS AND METHODS: From January 2001 to December 2001, 87 patients underwent distal (43), total (28), proximal (7) and partial gastrectomy (9) for gastric cancer (stage IA: 47, IB: 9, II: 7, IIIA: 8, IIIB 2, IV: 10) and gastrointestinal stromal tumor (4).
  • In the east building 47 patients were looked after according to the clinical pathway (path group) and 2 patients were excluded from the path group because of neo-adjuvant chemotherapy and severe heart failure.
  • CONCLUSION: A clinical pathway for gastrectomy patients proved useful to optimize their postoperative care, including medication management and diet education.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12928729.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement